Serial Amnioinfusions Yield 65.5% Early Survival in Fetal Kidney Failure

The RAFT trial delivered repeated isotonic fluid infusions into the amniotic sac for 32 pregnancies complicated by anhydramnios from urinary tract obstruction or dysplasia. More than 90% of births occurred before 37 weeks, yet 65.5% of neonates survived the first two weeks and tolerated peritoneal dialysis catheter placement. This outcome marks the first interventional series showing lung rescue sufficient for postnatal renal replacement therapy in a condition previously considered uniformly lethal.

Prior fetal therapy literature, including the 2023 RAFT report on bilateral renal agenesis and observational series in Fetal Diagnosis and Therapy, documented pulmonary hypoplasia as the dominant mortality driver. The current data extend benefit to obstructive etiologies but expose prematurity as the next rate-limiting step, with 34-week infants facing substantially higher dialysis complications than near-term counterparts.

Multidisciplinary coordination between fetal therapy and neonatal nephrology teams proved essential, yet the study leaves unanswered whether neurodevelopmental trajectories or long-term dialysis dependence differ from historical cohorts managed without prenatal fluid replacement. RAFT 2 will test refined infusion schedules aimed at extending gestation by at least two weeks.

Future protocols must incorporate standardized neurocognitive assessments at 18-24 months and compare costs against comfort-care pathways to guide equitable implementation.